Tegoprazan

- Expansion follows an exclusive License and Supply Agreement signed in 2024 with Tabuk Pharmaceuticals for K-CAB in ten countries in the Middle East and North Africa - K-CAB has now entered 54 countries worldwide and is continuing its global expansion K-CAB, HK inno.N’s new drug for gastroesophageal reflux disease (GERD), is expanding its presence in the global market. HK inno.N announced on the 7th (MAY 7) that the company recently expanded its collaboration with Tabuk Pharmaceuticals for K-CAB tablets (active ingredient tegoprazan), its new GERD treatment, to include additional six countries in the MENA region. HK inno.N signed an Agreement with Tabuk Pharmaceuticals in 2024 to for the exclusive License and Supply rights in 10 countries in the Middle East and North Africa. The new agreement with Tabuk Pharmaceuticals will expand the territory to include 6 new MENA countries; Egypt, Sudan, Ethiopia, Morocco, Yemen, and Libya. In addition to exporting technology, K-CAB is expanding its global presence through the export of finished products. Including this agreement, the company has reached a total of 53 overseas countries, excluding Korea. Tabuk Pharmaceuticals is a leading Saudi pharmaceutical company with a regional presence in the Middle East and North Africa with strong distribution and marketing capabilities across the Middle East and North Africa and is expected to play an important role in the market penetration and expansion of K-CAB in the MENA region. Kwak Dal-won, CEO of HK inno.N, said, “With this agreement, we have reached 53 countries, more than halfway to our goal of reaching 100 countries by 2028. We will continue to work closely with our partners in each country to establish K-CAB as a paradigm-shifting new drug for the treatment of GERD worldwide.” Ismail Shehada, CEO of Tabuk, said “We consider our partnership with HK inno.N to be a strategic pillar of our growth. We are pleased to expand our collaboration not only by extending our presence into additional countries, but also by broadening our portfolio with new products in the future. This reinforces our shared commitment to improving patient access and delivering innovative healthcare solutions globally. ” K-CAB, the 30th new drug in South Korea, is a P-CAB class new drug for GERD treatment and is addressing the market with various formulations (IR tablets, oral disintegrating tablets) and indications (5 in total). It is characterized by rapid onset of action within one hour after administration and proven efficacy and safety even with long-term use for up to six months. Following its first launch in South Korea, K-CAB succeeded in the market entry to a total of 54 countries worldwide and has been officially released in 15 countries to date. K-CAB recorded total outpatient prescription sales of KRW 196.9 billion in 2024 in South Korea. The product has been the steady No. 1 market leader in peptic ulcer medications for five consecutive years. [The End] [Reference information] ■ P-CAB: Potassium Competitive Acid Blocker ■ Overview of K-CAB’s market presence worldwide (54 countries in total): - South Korea, China, Mongolia, India, South Africa, the United States, Canada, Australia, New Zealand - 6 Southeast Asian countries: Indonesia, Thailand, Philippines, Vietnam, Singapore, Malaysia - 5 Eastern European countries: Russia, Kazakhstan, Uzbekistan, Ukraine, Belarus - 18 Central and South American countries: Brazil, Mexico, Argentina, Colombia, Peru, Chile, Ecuador, Uruguay, Paraguay, Bolivia, Venezuela, Dominican Republic, Guatemala, Honduras, Nicaragua, Costa Rica, Panama, El Salvador - 16 Middle Eastern/North African countries: Saudi Arabia, Jordan, Lebanon, UAE, Oman, Kuwait, Bahrain, Iraq, Qatar, Algeria, Egypt, Sudan, Ethiopia, Morocco, Yemen, Libya

4月29日上午，“引领城市年轻力”临沂市纪念五四运动106周年暨青年发展型城市主题宣讲交流活动在临沂大学沂蒙大讲堂盛大举行。临沂大学党委书记王焕良，市委副书记戚军，市委常委、市委宣传部部长、教育工委书记张晓彬，临沂大学党委副书记崔晓红，市委组织部副部长、市委人才发展服务中心主任李玉法，团市委书记程志强等领导以及市青年工作联席会议成员单位的有关负责同志，各县区（开发区）团（工）委书记，各领域优秀青年代表齐聚一堂，共同参与并见证了这场青春盛会。 图为活动现场 罗欣药业集团董事长兼CEO刘振腾作为青年企业家代表出席活动，并在“新时代青年说”环节以“创新转型的破局者”身份，向全市青年分享了他带领本土药企创新发展的奋进之路。 关于如何平衡个人理想与传承责任，他这样说道：“罗欣药业自1988年创立至今已37个年头，我们始终秉承‘传递健康’使命，致力于为百姓提供可及的创新药物。我的理想是让身边人远离病痛，而父亲创建的企业为我提供了实现梦想的土壤。尽管创新药的研发与上市充满了挑战，但是为了实现理想，也为了更好地传承，我坚定地选择了这条更难的道路。历经十年研发的1.1类创新药泰欣赞®于三年前在国内上市，成为山东省第一个化学一类新药。今年一季度，企业凭借创新药产品的优异市场表现成功实现扭亏为盈，这充分印证了创新转型战略对企业可持续发展的核心价值”。 图为罗欣药业集团董事长刘振腾接受采访 关于企业将如何在“新质生产力”的浪潮中把握机遇并实现企业发展目标 ，刘振腾董事长表示，罗欣药业正以创新药为核心，加速新动能培育。未来2-3年，公司普卡那肽等3款创新药有望在国内获批上市，从而进一步满足中国患者的临床需求。 不仅如此，他还带领罗欣药业全面推进人才战略升级，通过不断强化年轻化、专业化的团队建设，持续提升团队的“年轻力”“创造力”，从而全面提升企业核心竞争力，助力企业创新、高效、可持续发展。 刘振腾董事长“以创新驱动发展”“以责任回馈社会”的躬身实践，充分展现了新时代青年在传承中创新、在责任中成长的使命与担当，也激励着所有罗欣青年奋发向上，勇于筑梦！